Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Neurotrophic receptor kinase (NTRK) fusions drive various pediatric and adult solid tumors, making tropomyosin receptor kinase (TRK) a key therapeutic target.
• First-generation TRK inhibitors (larotrectinib, entrectinib) face resistance due to on-target mutations.
• Second-generation inhibitors (selitrectinib, repotrectinib) were developed to overcome first-generation resistance but are still subject to acquired resistance.

Purpose of the Study:

• To summarize acquired resistance mechanisms to first- and second-generation TRK inhibitors.
• To introduce emerging selective type II TRK inhibitors as a strategy to overcome specific resistance mutations.
• To discuss future challenges and directions in TRK inhibitor development.

Main Methods:

• Review of existing literature on TRK inhibitor resistance mechanisms.
• Analysis of structural and functional data related to TRK mutations and inhibitor binding.
• Discussion of novel therapeutic strategies targeting resistant TRK mutations.

Main Results:

• Identified xDFG and certain double mutations as key resistance mechanisms against current TRK inhibitors.
• Highlighted the potential of selective type II TRK inhibitors to overcome xDFG-mediated resistance.
• Emphasized the ongoing need for novel therapeutic approaches to address acquired resistance.

Conclusions:

• Acquired resistance to TRK inhibitors, particularly xDFG mutations, remains a significant clinical challenge.
• Emerging type II TRK inhibitors show promise in overcoming specific resistance mechanisms.
• Continued research into novel inhibitors and combination therapies is crucial for improving outcomes in NTRK fusion-positive cancers.